Clavis Pharma ASA expects to report top-line Phase 3 results for its compound for acute myeloid leukaemia (AML) by the end of the first quarter. The compound, elacytarabine, is a derivative of cytarabine- the licensed AML chemotherapy.
Ablynx NV has reported further efficacy data for its early-stage rheumatoid arthritis drug ALX-0061 which showed that up to 75% of patients achieved remission as defined by the DAS28 measure of disease activity at week 24 in a Phase 2 study.
Eli Lilly and Company has decided to stop development of the monoclonal antibody, tabalumab, in rheumatoid arthritis due to lack of efficacy. But it will continue to investigate the same drug as a possible treatment for systemic lupus erythematosus.
The Roche Group said its candidate antibody for haematological cancers, obinutuzumab, met its primary endpoint in the first stage of a Phase 3 trial and will now move on to be compared directly with MabThera/Rituxan (rituximab), the standard of care for leukaemias and lymphomas.
The licensed Amgen Inc medicine Aranesp (darbepoetin alfa) failed to meet its primary endpoint in a Phase 3 trial that was investigating the drug in a new heart failure indication. There were no new safety findings identified in the study.
ArGEN-X BV has announced the initiation of a Phase 1b clinical study in cancer patients of a new antibody targeting CD70, a member of the tumour necrosis factor superfamily. The company also announced an expansion of its discovery alliance with Shire Plc.
ISA Pharmaceuticals BV of the Netherlands has secured €8 million in funding from the Aglaia Oncology Fund and private investors to finance a Phase 2 study of its lead therapeutic vaccine candidate in cervical cancer. This a follow-on to an earlier Series A round.
GlaxoSmithKline Plc of the UK said that top-line results from a Phase 3 trial of an experimental drug for Fabry disease failed to meet its primary endpoint of clearing a lipid substra
Two out of the three patients with chronic lymphoid leukaemia (CLL) who were treated with a novel immunotherapy in 2010 remain healthy and in full remission more than two years after treatment, according to University of Pennsylvania researchers.
Sanofi SA has reported data from a Phase 2 trial of a Janus Kinase 2 (JAK2) inhibitor in myelofibrosis which showed the therapy achieved reductions in spleen size and other disease symptoms in 31 randomised patients.